{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-026280","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2026-08-06T20:17:59+00:00","discovered_at":"2026-08-06T20:19:00.277954+00:00","generated_at":"2026-08-06T20:21:22.206655+00:00","sec_items":[],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaxart reports Q2 2026 net loss $13.5M; Phase 2b sentinel safety data positive","bullets":["Net loss $13.5M ($0.06 per share) vs $15.0M loss in Q2 2025; revenue $27.2M (down from $39.7M).","Cash $64.0M; runway into Q2 2027; BARDA contract total authorized funding $344.8M.","Phase 2b sentinel cohort (400 participants) showed no vaccine-related SAEs; most common AEs: fatigue, headache.","Topline efficacy data from full ~5,000-participant study expected H1 2027.","R&D expenses $33.7M (down 32% YoY); G&A $6.6M (up 43% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-026280","json":"https://secwatch.observer/filing/0001437749-26-026280.json","markdown":"https://secwatch.observer/filing/0001437749-26-026280.md","text":"https://secwatch.observer/filing/0001437749-26-026280.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/0001437749-26-026280-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774926026280/vxrt20260806_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:21:22.206655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}